All In MedTech

Device Trial Radar · NCT05879081

Clinical Performance of Masimo MightySat Rx in Pediatric Populations

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

May 4, 2023

Primary completion

Jul 10, 2023

Study completion Jul 10, 2023

Sponsor

Lead sponsor
Masimo CorporationPublic (MASI)
Sponsor type
Industry
First posted
May 30, 2023

More device trials from this sponsor

Design

Study type
Interventional
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Other
Who can join
All sexes, from 5 years, up to 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a prospective, non-randomized data collection study to evaluate the clinical performance of the Masimo MightySat Rx in pediatric populations.

Conditions

  • RRP (Respiration Rate From PPG)

Interventions

  • Masimo MightySat RxDevice

    Masimo MightySat Rx will be used to measure respiratory values.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RRp (Respiration Rate From PPG) Performance of MightySat Rx in Pediatric Populations Meets Its Performance Specifications.Time frame: Approximately 15 minutes

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.